ArticleJournal of comparative effectiveness research2026
US population-level model of clinical impact of lorlatinib treatment on ALK+ metastatic non-small cell lung cancer outcomes.
Adam Kasle et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.